Mr. Stephen Van Deventer reports

BIOGENE THERAPEUTICS APPOINTS PATROSKI J. LAWSON TO BOARD OF DIRECTORS

Preveceutical Medical Inc.'s wholly owned subsidiary BioGene Therapeutics Inc. has appointed Patroski J. Lawson as an independent director, effective on Dec. 6, 2024.

Stephen Van Deventer, chief executive officer of BioGene, commented: "We are honoured to welcome Patroski Lawson to our board of directors. His extensive experience in government affairs across local, state, federal and global levels, particularly within the health care sector, will be invaluable as we navigate the complex regulatory landscape and advance our mission to deliver innovative therapies. Patroski's strategic insights and leadership will significantly enhance our governance and advocacy efforts."

About Mr. Lawson

Mr. Lawson brings over 25 years of experience in government affairs, spanning both public and private sectors. He began his career as a regional representative for U.S. Senator Paul D. Coverdell, liaising with government officials and leading anti-drug outreach initiatives.

In the private sector, Mr. Lawson managed political involvement programs and corporate political action committees at The Home Depot. He further honed his expertise in health care government affairs at Solvay Pharmaceuticals, Abbott and Lundbeck, leading lobbying and advocacy efforts in Brussels, Washington, D.C., and various U.S. state capitals.

Notably, he was instrumental in securing a $300-million federal contract from the U.S. Department of Health and Human Services to build the first cell-based influenza vaccine facility in the United States.

In 2017, he founded KPM Group DC, a concierge public affairs firm providing strategic guidance to clients in need of comprehensive government affairs solutions.

He holds a BS in political science with a concentration in urban geography and an MS in urban and regional planning, both from the Florida State University.

Mr. Lawson remarked on his appointment: "I am thrilled to join BioGene's board of directors and contribute to the company's mission of advancing transformative therapies. BioGene's dedication to addressing critical unmet medical needs aligns with my passion for strategic advocacy and public affairs. I look forward to supporting the company's growth and success."

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies, utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.